Stakeholders: Colistin Resistance Underscores Need For Congressional Action

May 27, 2016 at 2:35 PM
Stakeholders point to the detection of bacteria resistant to a last-resort drug as a reason to accelerate government efforts to combat antimicrobial resistance through increased surveillance and development of new antibiotics. Sen. Michael Bennet (D-CO) urges passage of his bill to accelerate approval of antibiotics for a limited population, and the HHS says the discovery is a reason for lawmakers to move forward with increased funding for efforts to combat antibiotic resistance. The Department of Defense notified stakeholders earlier in...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.